Vincerx Pharma, Inc. (VINC) Cash Flow Statement
Where VINC’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$26.1M
- Capital expenditures
- $0
- Free cash flow
- −$26.1M
- Returned to shareholders
- —
- Change in cash
- −$7.8M cash at year-end $5.1M
Drawn to scale: where the cash came from and how it was used. Hover for values.
VINC operating cash flow, capex and free cash flow
VINC cash flow trends, 2019–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$34,9992019 | −$26.1M2024 | — | |
| Capital expenditures | $258,0002019 | $02024 | −100.0% | |
| Free cash flow | −$34,9992019 | −$26.1M2024 | — | |
| Stock-based compensation | $1,2002019 | $3.5M2024 | +392.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
VINC cash flow by activity
VINC net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
VINC cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$30.1M | −$40.2M | −$65.4M | −$39.3M | −$10.4M | −$54,000 |
| Depreciation & amortization | $1.1M | $915,000 | $939,000 | $340,000 | $20,000 | $54,000 |
| Stock-based compensation | $3.5M | $3.6M | $10.1M | $23.3M | $4.4M | $1,200 |
| Change in working capital | −$178,000 | −$4.2M | −$1.0M | $5.6M | −$959,000 | $10,800 |
| Other non-cash items | −$438,000 | −$583,000 | −$4.2M | −$23.4M | $4.7M | −$46,999 |
| Cash from operating activities | −$26.1M | −$40.5M | −$59.6M | −$33.4M | −$2.3M | −$34,999 |
| Investing activities | ||||||
| Capital expenditures | $0 | $0 | $0 | −$5.3M | −$258,000 | −$258,000 |
| Investments (net) | $212,000 | $15.4M | −$40.6M | −$5.3M | $0 | — |
| Acquisitions & other investing | $0 | $26.1M | $0 | $5.3M | −$65.4M | −$65.4M |
| Cash from investing activities | $212,000 | $41.5M | −$40.6M | −$5.3M | −$65.6M | −$65.6M |
| Financing activities | ||||||
| Share repurchases & issuance (net) | — | — | — | — | $1,000 | — |
| Shares issued | $17.9M | $0 | $0 | $47.4M | $0 | $0 |
| Other financing | $118,000 | $114,000 | $280,000 | $41.0M | $64.1M | $66.5M |
| Cash from financing activities | $18.0M | $114,000 | $280,000 | $88.5M | $64.1M | $66.5M |
| Summary | ||||||
| Net change in cash | −$7.8M | $1.1M | −$99.8M | $49.8M | $61.8M | $790,036 |
| Cash at end of period | $5.1M | $12.9M | $11.7M | $111.6M | $61.8M | −$34,999 |
| Free cash flow | −$26.1M | −$40.5M | −$59.6M | −$38.7M | −$2.3M | −$34,999 |
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$5.0M | −$8.0M | −$7.8M | −$1.8M | −$12.4M | −$5.0M | −$9.7M | −$11.2M | −$14.3M | −$13.6M | −$16.9M | −$18.4M |
| Depreciation & amortization | $13,000 | $281,000 | $275,000 | $270,000 | $264,000 | $258,000 | $254,000 | $249,000 | $154,000 | $241,000 | $236,000 | $232,000 |
| Stock-based compensation | $435,000 | $610,000 | $1.4M | $912,000 | $528,000 | $457,000 | $1.3M | $385,000 | $1.4M | $1.5M | $2.3M | $3.4M |
| Change in working capital | −$1.6M | $1.5M | −$451,000 | $125,000 | −$1.3M | −$3.8M | $1.7M | −$2.4M | $375,000 | −$1.7M | −$541,000 | $142,000 |
| Other non-cash items | $1.7M | −$532,000 | $217,000 | −$5.3M | $5.2M | $32,000 | −$205,000 | $254,000 | −$664,000 | −$204,000 | $22,000 | −$1.2M |
| Cash from operating activities | −$4.5M | −$6.2M | −$6.4M | −$5.8M | −$7.7M | −$8.0M | −$6.6M | −$12.7M | −$13.1M | −$13.8M | −$14.9M | −$15.9M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | $7.2M | $1.4M | −$8.3M | $0 | $5.8M | $15.1M | $14.8M | $5.9M | −$20.4M | −$20.2M | −$20.2M |
| Acquisitions & other investing | — | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from investing activities | — | $7.2M | $1.4M | −$8.3M | — | $5.8M | $15.1M | $14.8M | $5.9M | −$20.4M | −$20.2M | −$20.2M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | $3,000 | — | — | — |
| Shares issued | $3.9M | $961,000 | $0 | $16.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $0 | $24,000 | $0 | $89,000 | $5,000 | $18,000 | $0 | $93,000 | $0 | $38,000 | $38,000 | $242,000 |
| Cash from financing activities | $3.9M | $985,000 | $0 | $17.0M | $5,000 | $18,000 | $0 | $93,000 | $3,000 | $38,000 | $38,000 | $242,000 |
| Summary | ||||||||||||
| Net change in cash | −$547,000 | $2.0M | −$5.0M | $2.8M | −$7.7M | −$2.3M | $8.4M | $2.2M | −$7.2M | −$34.1M | −$35.1M | −$15.6M |
| Cash at end of period | $4.5M | $5.1M | $3.0M | $8.0M | $5.2M | $12.9M | $15.1M | $6.7M | $4.6M | $11.7M | $45.9M | $80.9M |
| Free cash flow | −$4.5M | −$6.2M | −$6.4M | −$5.8M | −$7.7M | −$8.0M | −$6.6M | −$12.7M | −$13.1M | −$13.8M | −$14.9M | −$15.9M |
| Free cash flow margin | — | −578.7% | — | — | — | −610.3% | — | — | — | — | — | — |
| Capex / revenue | — | 0.0% | — | — | — | 0.0% | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
VINC cash generation
In fiscal 2024 (ended December 31, 2024), Vincerx Pharma generated -$26.1 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$26.1 million. Cash and equivalents fell by $7.8 million over the year.
Related: VINC income statement, VINC balance sheet. See the VINC stock overview for the latest quote and news.
VINC cash flow FAQ
What is Vincerx Pharma's free cash flow?
Vincerx Pharma's free cash flow was -$26.1 million in fiscal 2024: -$26.1 million of operating cash flow minus $0 of capital expenditures It was -$40.5 million a year earlier..
How much cash does Vincerx Pharma generate from operations?
Vincerx Pharma generated -$26.1 million of cash from operating activities in fiscal 2024.